Can an inhaled drug ease bronchiectasis? a trial seeks answers
NCT ID NCT07731919
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial tests an inhaled investigational drug called ALX1 in adults with bronchiectasis, a chronic lung condition that causes coughing and mucus buildup. Participants receive either ALX1 or a placebo for 14 days. The study aims to find safe and effective doses for future research by monitoring side effects and changes in key biomarkers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an inhaled investigational drug called ALX1
- What this could lead to
- If it works, this could point toward a new inhaled treatment for bronchiectasis, a chronic lung condition.
- What could go wrong
- This is an early phase 2a trial with only 28 participants, so results may not apply to everyone. The drug is inhaled and could cause side effects like changes in blood oxygen or heart rhythm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mapping patient profiles unlock better breathing therapy for bronchiectasis?
- Breathing and qigong: a drug-free approach to easier breathing for damaged lungs?
- Could your own lung cells heal damaged airways? a new trial aims to find out
- New drug CTX-187 takes aim at stubborn bacterial infections
- Lung patients may soon do rehab from home via app
- New study aims to find best exercise test for lung disease patients